The following questions with regards to patients treated in your trust are being asked for on behalf of Novartis.
1. In total, over the past 4 months, how many patients have been treated for the following diseases Rheumatoid arthritis, Axial Spondyloarthritis, Psoriatic arthritis, Psoriasis, hidradenitis suppurativa.?
2. Of these five, how many of each received the following products:
– Adalimumab Humira.
– Adalimumab Biosimilar
– Etanercept Enbrel.
– Etanercept Biosimilar
– Infliximab Remicade.
– Infliximab biosimilar
– Golimumab Simponi.
– Tofacitinib Xeljanz.
– Ustekinumab Stelara.
– Vedolizumab Entyvio.
– Filgotinib Jyseleca.
– Abatacept Orencia.
– Baricitinib Olumiant.
– Certolizumab Pegol Cimzia.
– Rituximab MabThera.
– Rituximab Biosimilar
– Tocilizumab RoActemra.
– Sarilumab Kevzara.
– Apremilast Otezla.
– Secukinumab Cosentyx.
– Isekizumab Taltz.
– Guselkumab Tremfya.
– Brodalumab Kyntheum.
– Risankizumab Skyrizi.
– Tildrakizumab Ilumetri.
– Upadacitinib Rinvoq.
– Bimekizumab Bimzelx.
3. Could you please provide the number of these patients that were treated within the gastro department still split by disease and treatment..
4. Over the same time period, how many patients for each of the five diseases Rheumatoid arthritis, Axial Spondyloarthritis, Psoriatic arthritis, Psoriasis, hidradenitis suppurativa. received the following treatments as their first ever biologic treatment?
– AxSPA
– PsA
– PsO
Thank you for taking the time to answer these questions, and I look forward to your response.